Siska Van Bruwaene

Urologist. Life enthusiast.

[Declan Murphy @declangmurphy]

@SiskaVB @EveraertsW @piet_ost @shanekronos It’s quite amazing!! PLND appears to have disappeared from the updated Prostate Cancer #EAUGuidelines! Now aligns with practice in Australia 10 years into the PSMA era #EAU24

[Siska Van Bruwaene @SiskaVB]

@declangmurphy @EveraertsW @piet_ost @shanekronos So … I indeed cannot seem to find a recommendation anymore in favor of PLND in the new guidelines 😮 I must admit I am a bit confused, what should we fight against now 🤷‍♀️😁

[Alexander Kutikov MD @uretericbud]

🔬💊 #TherapeuticNodeYield ➡️ #WillRogers 🤠 + #BiasMirage 🔮 as long anticipated

https://t.co/KroJH7LueI @KBGinsburg #ASCO23

[Alexander Kutikov MD @uretericbud]

🔬ePLND in #BladderCancer 🏥

😞 More harm. ❌Zero benefit

📚Level I evidence from @SWOG👩‍⚕️👨‍⚕️

https://t.co/4sq6jsXkjF

(tnx @KBGinsburg for alway being the first to find the good stuff!) #ASCO23 @ASCO

[Siska Van Bruwaene @SiskaVB]

@DrDeanElterman @MaartenAlbersen @MikkelFode @faysal_a_yafi @cgratzke Damn, missed you at EAU!!

[Matt Cooperberg @dr_coops]

ProtecT 15 yr: ⁦@Freddie_Hamdy⁩ taking on misconceptions, and conclusions. #eau23

Thoughts #pcsm??

[Murat Akand @muratakand06]

Check out our latest paper on "Quality Control Indicators for TURBT"
#bladdercancer @EurUrolOncol
https://t.co/40ARQGJgpa
@CaBLe_UZL @TimMuilwijk @FrankVanderAa6 @joniau @yraskin @SiskaVB @KathyVanderEeckt @BenVanCleynenbreugel @CedricJorissen
@UZLeuven @VznkuL

[Alastair Lamb @LambAlastair]

15yr f/u for #ProtecT_Trial just out!
•n=1610
•1/3 IR or HR by NCCN criteria
•n=45 DS deaths (AM17:RP12:RT16)
•n=104 mets (AM51:RP26:RT27)
•n=151 started ADT (AM69:RP40:RT42)
•62% of AS cross over to radical

Surprised? Or no surprises??

#EAU23 #Oxford_Urology @BAUSurology

[Siska Van Bruwaene @SiskaVB]

@LambAlastair @BAUSurology @Freddie_Hamdy @NEJM @NDSurgicalSci @OxfordMedSci @dr_coops @SigridCarlsson @BJUIjournal @OxfordCancer @JimCatto @LabBryant So 62% of active treatment in AS group and still double risk of mets. That’s not reassuring (if avoiding mets would be the goal of course).

[Alastair Lamb @LambAlastair]

Guess this is key slide from Freddie's talk. It's given me a bit of an existential crisis over past 36hrs

Should we approach all localised #ProstateCancer like we now do salvageRT?
i.e. put EVERYONE on surveillance, then only treat those who 'progress'?? (1/3 were T3!)

#EAU23

[Andries Clinckaert @andries_c]

Lymphedema after prostate cancer treatment? For many, it remains the forgotten vascular disease.
👉 Find out in our systematic review https://t.co/ETSobktE5O #mdpicancers via @Cancers_MDPI @joniau @EveraertsW @LisaMoris2

[UroToday.com @urotoday]

When low-volume on conventional imaging goes into high-volume on next-generation imaging in #mHSPC - treat like low-volume. #APCCC22 presentation by @fizazi_karim @GustaveRoussy. #ReadNow on UroToday > https://t.co/4IdLuLbtyd @APCCC_Lugano @Silke_Gillessen @AOmlin

[Shankar Siva @_ShankarSiva]

Late breaking abstracts #ASTRO22 - @ChadTangMD EXTEND trial; oligometastatic #prostatecancer. Intermittent ADT + SABR versus ADR alone extends PFS, but importantly time men enjoy off ADT in the long term (eugonadal PFS). Important patient centric endpoint! 👏🏽⭐️ @OncoAlert #pcsm

[Prof Ananya💙 @achoud72.bsky.social @achoud72]

@Prof_Nick_James on the association between volume & radiotherapy in #metastaticprostatecancer Is 4 the magic no for mets? How important is LN burden? Can men with mets be cured? 🤔 #PROSCA22 @mirrorsmed

[Siska Van Bruwaene @SiskaVB]

Just when you thought to grasp oligo-metastatic disease …@juliarmurray helping to see the light #PROSCA22

[Prof Ananya💙 @achoud72.bsky.social @achoud72]

D2 #PROSCA22 in beautiful Athens
@Silke_Gillessen outlines the evidence for #docetaxel in #mHSPC
Is volume of disease important? Does it matter if synchronous v metachronous disease? Triple v doublet therapy? @mirrorsmed @Prof_Nick_James

[Siska Van Bruwaene @SiskaVB]

Amit Bahl warning to perform imaging in mCRPC even when PSA is stable. #PROSCA22

[Siska Van Bruwaene @SiskaVB]

@AlbertoBossial gives us surgeons an important task : organize some phase III trials like we do 😁 #PROSCA22

[Siska Van Bruwaene @SiskaVB]

Some Stampede high risk patients might be cured with surgery alone instead of ‘suffering’ 2 years of intensified hormonal treatment. #PROSCA22 @joniau excellent talk

[Siska Van Bruwaene @SiskaVB]

@Achard_Verane Very clear talk at #PROSCA22 PSMA in BCR setting is interesting but creates a lot of new questions!